Address: Room 1805-1806 388, Nanjing West Road,
Ciro’s Plazza,
Shanghai 200003, China
Tel: 0086 21 6237 5707
Web: http://www.ethypharm.com/
Based in France, Ethypharm is a world leading Drug Delivery System (DDS) company providing effective solutions to optimize delivery of active pharmaceutical ingredient into the human body. Ethypharm provides suitable life cycle management opportunities to existing commercial pharmaceutical products. The company has developed a broad range of technology platforms for oral delivery with a special focus on modified release formulation as well as orodispersible dosage forms. The Chinese subsidiary has a particular focus on collaborating with local partners to develop DDS platforms for Traditional Chinese Medicines in addition to the global product platforms.
Drug Delivery Systems
A roundup of some of the biggest news stories from the pharma industry in China including Aspen’s purchase of Sandoz’s Chinese business; Moderna’s first mRNA facility in China; WuXi Biologics’…
A roundup of some of the latest news from Chinese pharma including CanSino’s Gates Foundation grant for polio vaccine R&D; Merck’s deal with Jiangsu Hengrui; the license agreement between GSK…
After four years away, Brendan Shaw recently returned to China to attend the ChinaBio Innovation and Investment Conference in Suzhou. Although geopolitical tensions, the fallout from COVID-19, and local market…
A roundup of some of the latest pharma news from China including Pfizer’s first Asia launch of Rimegepant migraine treatment in Hong Kong; Zhifei and GSK’s shingles vaccine deal, and…
A decade on from its launch, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative has made some significant wins but remains some way from fulfilling the vision of a fully…
Writing in the September 2023 edition of DIA’s Global Forum magazine, Shuting Li of Anhui Jimin Cancer Hospital and Xinfang Fan of Bayer Health Care Ltd. examine how Chinese clinical…
Ongoing geopolitical tensions between China and the West have led the G7 group of countries to warn of the threat of “economic coercion” from China and the US to scrutinise…
A roundup of some of the latest healthcare and pharma news from China including a crackdown on healthcare corruption; AstraZeneca’s cardiovascular mortality drug approval and mRNA manufacturing deal with CanSino;…
Writing in the August edition of DIA’s Global Forum magazine, Wen Yin of the Pfizer China R&D Center and Wanhe Deng of GSK China Investment look back on four years…
At a time when the country’s economy has fallen into a slump with the currency sinking to its lowest level in 16 years, Chinese giant Fosun Pharma continues to agressively…
A roundup of some of the biggest recent stories coming out of China, including the commerce minister’s peace offering to international drug companies; CSPC Pharmaceutical Group’s partnership with Pfizer; Merck’s…
A roundup of some of the most significant recent stories from the Chinese pharmaceutical industry, including a slate of international investment which seems to suggest that – despite ongoing political…
See our Cookie Privacy Policy Here
